Skip to main content

and
  1. No Access

    Article

    Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial

    In the HELIOS trial, bendamustine/rituximab (BR) plus ibrutinib (BR-I) improved disease outcomes versus BR plus placebo in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Here, we desc...

    Silvia Maria Lavezzi, Jan de Jong, Martine Neyens, Paula Cramer in Pharmaceutical Research (2019)